Once MSB seals at least one partnership deal with accompanying cash injection in O-6 months time, this will almost certainly negate the need for it raise any further cash via share issue ever again, due to likely outcomes:
A) issue of rare orphan paediatric drug voucher which it can sell for circa 250 - 300 million dollars quite easily. Should be received upon approval of ped acute GVHD by late 2017/ early 2018.
B) Steadily accumulating revenues from Temcell in Japan and from ped acute GVHD in US.
C) milestone payment of ~ 100/150 million upon approval of CHF product in the US. Est. 2018-2019.
Done.
Predictions do come true, page-11
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |